NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

(2017) Can Hekim et al.   Cancer Immunology Research

Human CD56dimCD16dim Cells As an Individualized Natural Killer Cell Subset

(2017) Mathieu Amand et al.   Frontiers in Immunology

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

(2016) Mohamed El Missiry et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

(2016) M Ilander et al.   LEUKEMIA

Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1

(2016) Wilfredo F Garcia-Beltran et al.   NATURE IMMUNOLOGY

Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies

(2016) Maxim Shevtsov et al.   Frontiers in Immunology

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

(2016) Emily M. McWilliams et al.   OncoImmunology

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study

(2015) Noriyoshi Iriyama et al.   AMERICAN JOURNAL OF HEMATOLOGY

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

(2015) L. Ruggeri et al.   HAEMATOLOGICA

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

(2015) L. Ruggeri et al.   HAEMATOLOGICA

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies

(2015) Angela Gismondi et al.   Frontiers in Immunology

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells

(2014) G. F. Torelli et al.   HAEMATOLOGICA

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence

(2013) Ciani Oriana et al.   VALUE IN HEALTH

Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells inin vitrostudy

(2012) Takayoshi Uchiyama et al.   HEMATOLOGICAL ONCOLOGY

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

(2012) Nicole Hassold et al.   INTERNATIONAL JOURNAL OF CANCER

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

(2012) Yoshiki Hayashi et al.   LEUKEMIA & LYMPHOMA

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

(2011) C I-U Chen et al.   LEUKEMIA

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

(2010) A. Kreutzman et al.   BLOOD

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

(2010) Julia Salih et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

(2010) Yasunobu Nagata et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

Dasatinib suppresses in vitro natural killer cell cytotoxicity

(2008) S. J. Blake et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo

(2008) Cara K. Fraser et al.   EXPERIMENTAL HEMATOLOGY

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

(2008) D. H. Kim et al.   HAEMATOLOGICA